Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 68

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 68
---
-employee director compensation policy also provides for equity compensation to each non-employee director as follows: • Initial Grant: At the time they join our Board, each new non-employee director will receive an initial stock option grant with a grant date fair value of $450,000, rounded to the nearest 500 shares, vesting annually over three years. • Annual Grant: Each non-employee director will receive an annual grant of equity awards in the form of stock options and RSUs at a 1:1 stock-option-to-RSU ratio calculated on the basis of such equity awards together having an aggregate grant date fair value of $300,000, rounded to the nearest 500 shares, vesting in full on the date of the next annual meeting of stockholders, subject to continued service. In March 2024, to further align the interests of the Board and the Company’s stockholders, the Human Capital Committee suspended the non-employee director compensation policy solely with respect to the annual grant to be made at the 2024 Annual Meeting of Stockholders. In lieu of grants that would otherwise have been made to non-employee directors under the non-employee director compensation policy, the Human Capital Committee granted 150,000 RSUs to each of the then serving non-employee directors, vesting in full on the date of the 2025 annual meeting of stockholders, subject to continued service through such date. All options granted to our non-employee directors under the policy will vest in full upon the completion of a change in control. Grant date option value is determined using the same method we use to calculate the grant date fair value of stock options in our financial statements. Equity Compensation Plan Information The following table provides certain information with respect to all of our equity compensation plans in effect as of December 31, 2024.

| Plan Category                                             |     | Number of      
 Securities to  
 be Issued upon 
 Exercise of    
 Outstanding    
 Options and    
 RSUs           |         |     | Weighted-   
 Average     
 Exercise    
 Price of    
 Outstanding 
 Options     |        |     | Number of      
 Securities     
 Remaining      
 Available for  
 Future         
 Issuance Under 
 Equity         
 Compensation   
 Plans(1)       |         |
|:----------------------------------------------------------|:----|:---------------|--------:|:----|:------------|-------:|:----|:---------------|--------:|
| Equity Compensation Plans Approved by Stockholders(2)     |     |                | 599,974 |     | $           |